 "DCGI gives nod to Natco & Hetero to produce Gilead's hepatitis C drug")
Two Hyderabad-based companies, Natco Pharma and Hetero Drugs – have received Drugs Controller General-India (DCGI) approvals for manufacturing Gilead's hepatitis C drug sofosbuvir.
Natco Pharma Limited, which received for the generic hepatitis C medicine sofosbuvir tablets of 400 mg, would market the product through strategic partners in India, according to a press release. Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
Similarly, Hetero Drugs, which had received approval for generic sofosbuvir tablets 400 mg from the DCGI, too has a non-exclusive agreement with Gilead Sciences to manufacture and sell its hepatitis medicines. The company said it would price its generic medicine at Rs 19,900 for a bottle of 28 tablets and would launch the medicine this month in India and other countries soon. It has tied up with various other licensee holders to distribute the medicine in India.
Natco Pharma Limited, which received for the generic hepatitis C medicine sofosbuvir tablets of 400 mg, would market the product through strategic partners in India, according to a press release. Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
Similarly, Hetero Drugs, which had received approval for generic sofosbuvir tablets 400 mg from the DCGI, too has a non-exclusive agreement with Gilead Sciences to manufacture and sell its hepatitis medicines. The company said it would price its generic medicine at Rs 19,900 for a bottle of 28 tablets and would launch the medicine this month in India and other countries soon. It has tied up with various other licensee holders to distribute the medicine in India.